DK47588A - Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose - Google Patents

Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose

Info

Publication number
DK47588A
DK47588A DK047588A DK47588A DK47588A DK 47588 A DK47588 A DK 47588A DK 047588 A DK047588 A DK 047588A DK 47588 A DK47588 A DK 47588A DK 47588 A DK47588 A DK 47588A
Authority
DK
Denmark
Prior art keywords
procedure
dna
protein
diagnosis
fragments
Prior art date
Application number
DK047588A
Other languages
English (en)
Other versions
DK47588D0 (da
Inventor
Benno Mueller-Hill
Jie Kang
Hans-Georg Lemaire
Axel Unterbeck
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DK47588D0 publication Critical patent/DK47588D0/da
Publication of DK47588A publication Critical patent/DK47588A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK047588A 1987-01-30 1988-01-29 Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose DK47588A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873702789 DE3702789A1 (de) 1987-01-30 1987-01-30 Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins

Publications (2)

Publication Number Publication Date
DK47588D0 DK47588D0 (da) 1988-01-29
DK47588A true DK47588A (da) 1988-07-31

Family

ID=6319874

Family Applications (1)

Application Number Title Priority Date Filing Date
DK047588A DK47588A (da) 1987-01-30 1988-01-29 Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose

Country Status (16)

Country Link
US (1) US5218100A (da)
EP (1) EP0276723B1 (da)
JP (2) JP2783407B2 (da)
KR (1) KR960011524B1 (da)
CN (1) CN1034576C (da)
AT (1) ATE98260T1 (da)
AU (1) AU603179B2 (da)
CA (1) CA1341033C (da)
DE (2) DE3702789A1 (da)
DK (1) DK47588A (da)
ES (1) ES2061527T3 (da)
HU (1) HUT46356A (da)
IL (1) IL85220A (da)
NZ (1) NZ223312A (da)
PH (1) PH25795A (da)
ZA (1) ZA88634B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
JPH03239595A (ja) * 1990-02-16 1991-10-25 Dainippon Printing Co Ltd カード製造方法
CA2101774C (en) * 1991-01-21 2011-01-04 John A. Hardy Test and model for alzheimer's disease
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
AU744755B2 (en) * 1997-11-12 2002-03-07 Brigham And Women's Hospital The translation enhancer element of the human amyloid precursor protein gene
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
JP2002521004A (ja) * 1998-07-10 2002-07-16 キュラゲン コーポレイション ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR100900541B1 (ko) 2002-11-14 2009-06-02 삼성전자주식회사 액정 표시 장치용 박막 트랜지스터 기판
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
RS53291B (sr) 2005-12-12 2014-08-29 Ac Immune S.A. Beta 1-42 specifična monoklonska antitela sa terapeutskim svojstvima
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2007336770A1 (en) * 2006-12-22 2008-07-03 Genentech, Inc. DR6 antibodies inhibiting the binding of DR6 to APP, and uses thereof in treating neurological disorders
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TW201518320A (zh) * 2007-06-12 2015-05-16 Ac Immune Sa 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102124336A (zh) * 2008-06-12 2011-07-13 健泰科生物技术公司 用于筛选抑制神经变性的化合物的方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
KR20120103587A (ko) * 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EP3697927B1 (en) * 2017-10-19 2022-12-14 Bio-Rad Laboratories, Inc. Digital amplification assays with unconventional and/or inverse changes in photoluminescence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
DE3752253T2 (de) * 1986-11-17 1999-05-27 Scios Inc Rekombiniertes Alzheimer Amyloid-Protein.

Also Published As

Publication number Publication date
ES2061527T3 (es) 1994-12-16
DE3886060D1 (de) 1994-01-20
CA1341033C (en) 2000-06-20
IL85220A (en) 1993-07-08
DK47588D0 (da) 1988-01-29
JP2783407B2 (ja) 1998-08-06
HUT46356A (en) 1988-10-28
EP0276723B1 (de) 1993-12-08
AU1064188A (en) 1988-08-04
EP0276723A3 (de) 1991-05-15
KR880009035A (ko) 1988-09-13
PH25795A (en) 1991-11-05
JPS63222693A (ja) 1988-09-16
DE3702789A1 (de) 1988-08-18
IL85220A0 (en) 1988-07-31
US5218100A (en) 1993-06-08
JPH10218899A (ja) 1998-08-18
ATE98260T1 (de) 1993-12-15
KR960011524B1 (ko) 1996-08-23
AU603179B2 (en) 1990-11-08
JP3513795B2 (ja) 2004-03-31
CN88100542A (zh) 1988-08-10
EP0276723A2 (de) 1988-08-03
CN1034576C (zh) 1997-04-16
ZA88634B (en) 1988-08-02
NZ223312A (en) 1991-10-25

Similar Documents

Publication Publication Date Title
DK47588D0 (da) Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose
DK0418035T3 (da) Levende vævsækvivalenter
DE3687833D1 (de) Chirurgisches ultraschall-instrument.
NO160114C (no) Blanding for bruk ved ekstern paavisning og lokalisering av blodpropp.
ES516033A0 (es) Mejoras introducidas en endoscopios combinados con instrumentos quirurgicos manuales rigidos.
DE69005840D1 (de) Analytisches Element zur Untersuchung des gesamten Blutes.
NO880268D0 (no) Fremgangsmaate for fremstilling av anti-koagulerende peptider.
ATE168135T1 (de) Diagnose von retinoblastoma
DE3887519D1 (de) Externe fixiervorrichtung für knochenchirurgie.
DE3783966D1 (de) Reagens zur pruefung von periodentalen erkrankungen.
ES2072490T3 (es) Procedimiento para la pasteurizacion de la proteina tisular pp4.
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
IT1206005B (it) Strumento geometrico e procedimento per la sua fabbricazione
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
EP0309566A4 (en) Stlv-iii-related polypeptides, diagnostic systems and assay methods.
DE3673996D1 (de) Medizinisches instrument zur knochenentfernung.
NO883626D0 (no) Fremgangsmaate for diagnose av kikhoste og testsett for utfoerelse av fremgangsmaaten.
DE3872790D1 (de) Geraet zur untersuchung von reissverschlusselementen.
NO883868D0 (no) Fremgangsmaate for diagnostisering av dsrna-mangeltilstander, samt fremgangsmaate for fremstilling av preparater for diagnostisering og behandling av slike tilstander.
NO882836L (no) Fremgangsmaate for kjemisk modifisering av protider (proteiner og peptider).
DK0386733T3 (da) cDNA, som koder for placentaprotein 9 (PP9), dets isolering og anvendelse
DE3788424D1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).
NO881610D0 (no) Antistoff og fremgangsmaate for dets fremstilling og anvendelse, saerlig for diagnose.
FI903637A0 (fi) Diagnostiska analysfoerfarande och deras anvaendning foer bestaemning av kliniska tillstaond.
NO860828L (no) Mikrokuler som ikke er radioaktivt merket og anvendelse derav for mÿling av blodstrÿmmen.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment